

Clara Balsano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6996450/publications.pdf>

Version: 2024-02-01

104
papers

4,555
citations

117625

34
h-index

106344

65
g-index

109
all docs

109
docs citations

109
times ranked

5591
citing authors

#	ARTICLE	IF	CITATIONS
1	The application of artificial intelligence in hepatology: A systematic review. <i>Digestive and Liver Disease</i> , 2022, 54, 299-308.	0.9	13
2	PaO ₂ /FiO ₂ ratio forecasts COVID-19 patients' outcome regardless of age: a cross-sectional, monocentric study. <i>Internal and Emergency Medicine</i> , 2022, 17, 665-673.	2.0	11
3	Using the Social Robot NAO for Emotional Support to Children at a Pediatric Emergency Department: Randomized Clinical Trial. <i>Journal of Medical Internet Research</i> , 2022, 24, e29656.	4.3	10
4	Copper-catalyzed dicarbonyl stress in NAFLD mice: protective effects of Oleuropein treatment on liver damage. <i>Nutrition and Metabolism</i> , 2022, 19, 9.	3.0	3
5	Children and Adolescents Dietary Habits and Lifestyle Changes during COVID-19 Lockdown in Italy. <i>Nutrients</i> , 2022, 14, 2135.	4.1	14
6	Alteration of Inflammatory Parameters and Psychological Post-Traumatic Syndrome in Long-COVID Patients. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 7103.	2.6	11
7	Liver-spleen axis in nonalcoholic fatty liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 759-769.	3.0	14
8	Age and Interleukin-15 Levels Are Independently Associated With Intima-Media Thickness in Obesity-Related NAFLD Patients. <i>Frontiers in Medicine</i> , 2021, 8, 634962.	2.6	16
9	Laboratory parameters related to severe disease and death in SARS-CoV-2 pneumonia: Retrospective analysis. <i>Journal of Medical Virology</i> , 2021, 93, 5886-5895.	5.0	6
10	Copper concentrations are prevalently associated with antithrombin III, but also with prothrombin time and fibrinogen in patients with liver cirrhosis: A cross-sectional retrospective study. <i>Journal of Trace Elements in Medicine and Biology</i> , 2021, 68, 126802.	3.0	2
11	Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis. <i>Metabolomics</i> , 2021, 17, 12.	3.0	37
12	Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 364.	8.6	15
13	It Is High Time Physicians Thought of Natural Products for Alleviating NAFLD. Is There Sufficient Evidence to Use Them?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13424.	4.1	61
14	Gastrointestinal peptides and nonalcoholic fatty liver disease. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2020, 27, 11-15.	2.3	7
15	The pharmacological treatment of nonalcoholic fatty liver disease in children. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 1219-1227.	3.1	3
16	Circulating Neutrophils of Nonalcoholic Steatohepatitis Patients Show an Activated Phenotype and Suppress T Lymphocytes Activity. <i>Journal of Immunology Research</i> , 2020, 2020, 1-15.	2.2	19
17	Could SCGF-Beta Levels Be Associated with Inflammation Markers and Insulin Resistance in Male Patients Suffering from Obesity-Related NAFLD?. <i>Diagnostics</i> , 2020, 10, 395.	2.6	56
18	Oleuropein overrides liver damage in steatotic mice. <i>Journal of Functional Foods</i> , 2020, 65, 103756.	3.4	10

#	ARTICLE	IF	CITATIONS
19	Is There a Link between Basal Metabolic Rate, Spleen Volume and Hepatic Growth Factor Levels in Patients with Obesity-Related NAFLD?. <i>Journal of Clinical Medicine</i> , 2019, 8, 1510.	2.4	11
20	Do Transferrin Levels Predict Haemodialysis Adequacy in Patients with End-Stage Renal Disease?. <i>Nutrients</i> , 2019, 11, 1123.	4.1	7
21	Prediction of carotid intima-media thickness in obese patients with low prevalence of comorbidities by serum copper bioavailability. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1511-1517.	2.8	41
22	Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study. <i>Internal and Emergency Medicine</i> , 2018, 13, 651-660.	2.0	29
23	Is copper a new target to counteract the progression of chronic diseases?. <i>Metallomics</i> , 2018, 10, 1712-1722.	2.4	43
24	Oleuropein Induces AMPK-Dependent Autophagy in NAFLD Mice, Regardless of the Gender. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3948.	4.1	36
25	Copper/MYC/CTR1 interplay: a dangerous relationship in hepatocellular carcinoma. <i>Oncotarget</i> , 2018, 9, 9325-9343.	1.8	30
26	Carotid plaque detection improves the predictive value of CHA2DS2-VASc score in patients with non-valvular atrial fibrillation: The ARAPACIS Study. <i>International Journal of Cardiology</i> , 2017, 231, 143-149.	1.7	22
27	Focal adhesion kinase depletion reduces human hepatocellular carcinoma growth by repressing enhancer of zeste homolog 2. <i>Cell Death and Differentiation</i> , 2017, 24, 889-902.	11.2	53
28	Evaluation of tolerance to ambulatory blood pressure monitoring. <i>Medicine (United States)</i> , 2017, 96, e9162.	1.0	8
29	Non-Alcoholic Fatty Liver Disease and Nutritional Implications: Special Focus on Copper. <i>Nutrients</i> , 2017, 9, 1137.	4.1	54
30	AISF position paper on liver transplantation and pregnancy. <i>Digestive and Liver Disease</i> , 2016, 48, 860-868.	0.9	20
31	Small heterodimer partner 1 directly interacts with NS5A viral protein and has a key role in HCV related liver cell transformation. <i>Oncotarget</i> , 2016, 7, 84575-84586.	1.8	9
32	Core domain mutant Y220C of p53 protein has a key role in copper homeostasis in case of free fatty acids overload. <i>BioMetals</i> , 2015, 28, 1017-1029.	4.1	8
33	Lymphocytes as Liver Damage Mirror of HCV Related Adipogenesis Deregulation. <i>PLoS ONE</i> , 2014, 9, e92343.	2.5	8
34	Normocaloric Low Cholesterol Diet Modulates Th17/Treg Balance in Patients with Chronic Hepatitis C Virus Infection. <i>PLoS ONE</i> , 2014, 9, e112346.	2.5	29
35	Plasma high mobility group box 1 protein reflects fibrosis in pediatric nonalcoholic fatty liver disease. <i>Expert Review of Molecular Diagnostics</i> , 2014, 14, 763-771.	3.1	22
36	Effects of the Olive-Derived Polyphenol Oleuropein on Human Health. <i>International Journal of Molecular Sciences</i> , 2014, 15, 18508-18524.	4.1	223

#	ARTICLE	IF	CITATIONS
37	MicroRNAs in Nonalcoholic Fatty Liver Disease: Novel Biomarkers and Prognostic Tools during the Transition from Steatosis to Hepatocarcinoma. <i>BioMed Research International</i> , 2014, 2014, 1-14.	1.9	62
38	Protective Effect of the Y220C Mutant p53 Against Steatosis: Good News?. <i>Journal of Cellular Physiology</i> , 2014, 229, 1182-1192.	4.1	16
39	Exocyclic DNA Adducts in a Murine Model of Non-alcoholic Steatohepatitis. <i>Journal of Carcinogenesis & Mutagenesis</i> , 2014, s3, .	0.3	0
40	Are Hedgehog and Wnt/ β -catenin pathways involved in hepatitis C virus-mediated EMT?. <i>Journal of Hepatology</i> , 2013, 58, 636-637.	3.7	7
41	Environmental Pollution: A Tangible Risk for NAFLD Pathogenesis. <i>International Journal of Molecular Sciences</i> , 2013, 14, 22052-22066.	4.1	63
42	Mitochondrial Dysfunctions and Altered Metals Homeostasis: New Weapons to Counteract HCV-Related Oxidative Stress. <i>Oxidative Medicine and Cellular Longevity</i> , 2013, 2013, 1-10.	4.0	27
43	Probiotics in non-alcoholic fatty liver disease: which and when. <i>Annals of Hepatology</i> , 2013, 12, 357-363.	1.5	32
44	Cardiovascular and Cerebrovascular Events Pre- and Post-Earthquake of 6 April 2009: The Abruzzo's Experience. <i>American Journal of Hypertension</i> , 2012, 25, 556-560.	2.0	17
45	Paradoxical prosteatotic effect of hedgehog signaling pathway inhibition under conditions of steatosis. <i>Hepatology</i> , 2012, 56, 1587-1588.	7.3	1
46	Inverse correlation between plasma oxysterol and LDL-cholesterol levels in hepatitis C virus-infected patients. <i>Digestive and Liver Disease</i> , 2012, 44, 245-250.	0.9	11
47	Hepatitis C in the elderly: A multicentre cross-sectional study by the Italian Association for the Study of the Liver. <i>Digestive and Liver Disease</i> , 2012, 44, 674-680.	0.9	17
48	Focal Adhesion Kinase (FAK) Mediates the Induction of Pro-Oncogenic and Fibrogenic Phenotypes in Hepatitis C Virus (HCV)-Infected Cells. <i>PLoS ONE</i> , 2012, 7, e44147.	2.5	23
49	Hepatitis C virus and alcohol: Same mitotic targets but different signaling pathways. <i>Journal of Hepatology</i> , 2011, 54, 956-963.	3.7	14
50	Effect of treatment with polyunsaturated fatty acids on HCV- or diet-induced fatty liver. <i>Journal of Hepatology</i> , 2011, 54, 1325-1326.	3.7	0
51	Regarding: Epithelial-Mesenchymal Transition Induced by Hepatitis C Virus Core Protein in Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2011, 18, 896-896.	1.5	3
52	Activation of the endotoxin/toll-like receptor 4 pathway: The way to go from nonalcoholic steatohepatitis up to hepatocellular carcinoma. <i>Hepatology</i> , 2011, 53, 1069-1069.	7.3	5
53	Hepatitis C virus therapeutics: Editing enzymes promising therapeutic targets?. <i>Hepatology</i> , 2011, 54, 742-742.	7.3	1
54	7 α -cholesterol and 5 β -cholesterol modulate differently the stress-activated mitogen-activated protein kinases (MAPKs) in liver cells. <i>Journal of Cellular Physiology</i> , 2010, 222, 586-595.	4.1	19

#	ARTICLE	IF	CITATIONS
55	Antioxidant Effects of Natural Bioactive Compounds. <i>Current Pharmaceutical Design</i> , 2009, 15, 3063-3073.	1.9	142
56	Functions and therapeutic value of focal adhesion kinase signaling during hepatocellular carcinoma development and progression. <i>Hepatology</i> , 2009, 51, n/a-n/a.	7.3	0
57	Liver Fibrosis and Therapeutic Strategies: The Goal for Improving Metabolism. <i>Current Drug Targets</i> , 2009, 10, 505-512.	2.1	28
58	Ketoprofen, peginterferon 2a and ribavirin for genotype 1 chronic hepatitis C: A phase II study. <i>World Journal of Gastroenterology</i> , 2009, 15, 5946.	3.3	3
59	Involvement of PI3K in HCV-related lymphoproliferative disorders. <i>Journal of Cellular Physiology</i> , 2008, 214, 396-404.	4.1	17
60	PKR is a novel functional direct player that coordinates skeletal muscle differentiation via p38MAPK/AKT pathways. <i>Cellular Signalling</i> , 2008, 20, 534-542.	3.6	23
61	Viral Hepatitis B: Established and Emerging Therapies. <i>Current Medicinal Chemistry</i> , 2008, 15, 930-939.	2.4	19
62	Recent Advances in Antiviral Agents: Established and Innovative Therapies for Viral Hepatitis. <i>Mini-Reviews in Medicinal Chemistry</i> , 2008, 8, 307-318.	2.4	5
63	Hepatitis C virus (HCV): an RNA virus with a pro-oncogenic potential. <i>Digestive and Liver Disease</i> , 2007, 39, S46-S51.	0.9	7
64	Hepatitis C virus core protein enhances B lymphocyte proliferation. <i>Digestive and Liver Disease</i> , 2007, 39, S72-S75.	0.9	14
65	Enhancing the Efficacy of Hepatocellular Carcinoma Chemotherapeutics with Natural Anticancer Agents. <i>Nutrition Reviews</i> , 2007, 65, 550-553.	5.8	8
66	Role of p38 MAPK and RNA-dependent Protein Kinase (PKR) in Hepatitis C Virus Core-dependent Nuclear Delocalization of Cyclin B1. <i>Journal of Biological Chemistry</i> , 2006, 281, 10983-10989.	3.4	43
67	HCV-Related Transformation and New Therapeutic Strategies: An Update. <i>Current Cancer Therapy Reviews</i> , 2006, 2, 41-56.	0.3	6
68	Thr 446 phosphorylation of PKR by HCV core protein deregulates G2/M phase in HCC cells. <i>Journal of Cellular Physiology</i> , 2005, 205, 25-31.	4.1	22
69	Physical and functional interaction between HCV core protein and the different p73 isoforms. <i>Oncogene</i> , 2003, 22, 2573-2580.	5.9	61
70	Differential regulation of E2F1 apoptotic target genes in response to DNA damage. <i>Nature Cell Biology</i> , 2003, 5, 552-558.	10.3	249
71	p73 Is Regulated by Phosphorylation at the G2/M Transition. <i>Journal of Biological Chemistry</i> , 2003, 278, 49196-49202.	3.4	37
72	Activation of RAF-1/MAPK/(727-Ser) STAT-1 pathway by HCV core protein causes a transcriptional induction of IFN- α inducible-genes. <i>Journal of Hepatology</i> , 2002, 36, 25.	3.7	0

#	ARTICLE	IF	CITATIONS
73	The Anti-apoptotic and pro-proliferative p53-related DN-p73 protein is expressed in human HCC. <i>Journal of Hepatology</i> , 2002, 36, 81-82.	3.7	0
74	DNA Damage-Dependent Acetylation of p73 Dictates the Selective Activation of Apoptotic Target Genes. <i>Molecular Cell</i> , 2002, 9, 175-186.	9.7	298
75	DN-p73 is activated after DNA damage in a p53-dependent manner to regulate p53-induced cell cycle arrest. <i>Oncogene</i> , 2002, 21, 3796-3803.	5.9	75
76	Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein. <i>Oncogene</i> , 2001, 20, 2606-2610.	5.9	135
77	Occult hepatitis B virus infection. <i>Digestive and Liver Disease</i> , 2000, 32, 822-826.	0.9	26
78	Nonsteroidal anti-inflammatory drug metabolism potentiates interferon alfa signaling by increasing STAT1 phosphorylation. <i>Hepatology</i> , 1999, 30, 510-516.	7.3	40
79	Tumor Necrosis Factor (TNF) Receptor 1 Signaling Downstream of TNF Receptor-associated Factor 2. <i>Journal of Biological Chemistry</i> , 1997, 272, 26079-26082.	3.4	106
80	The hepatitis B virus X gene induces p53-mediated programmed cell death. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997, 94, 8162-8167.	7.1	190
81	Activation of SAPK/JNK by TNF Receptor 1 Through a Noncytotoxic TRAF2-Dependent Pathway. <i>Science</i> , 1997, 275, 200-203.	12.6	450
82	MyoD prevents cyclinA/cdk2 containing E2F complexes formation in terminally differentiated myocytes. <i>Oncogene</i> , 1997, 14, 1171-1184.	5.9	43
83	p300 is required for MyoD-dependent cell cycle arrest and muscle-specific gene transcription. <i>EMBO Journal</i> , 1997, 16, 369-383.	7.8	257
84	Uncoupling of p21 induction and MyoD activation results in the failure of irreversible cell cycle arrest in doxorubicin-treated myocytes. <i>Journal of Cellular Biochemistry</i> , 1997, 66, 27-36.	2.6	13
85	FASAPO1 MUTATIONS AND DEFECTIVE FAS-MEDIATED APOPTOSIS IN A CHILD WITH TYPE 2a AUTOIMMUNE HEPATITIS.. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 1997, 24, 486.	1.8	0
86	Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to α -interferon therapy in chronic HCV hepatitis patients. <i>Journal of Hepatology</i> , 1996, 25, 212-217.	3.7	88
87	Infection of Circulating and Liver Infiltrating T Cells by Hepatitis C Virus of Different Subtypes. <i>Viral Immunology</i> , 1995, 8, 63-73.	1.3	14
88	Reactive Oxygen Intermediates Mediate Angiotensin II-induced c-Jun/c-Fos Heterodimer DNA Binding Activity and Proliferative Hypertrophic Responses in Myogenic Cells. <i>Journal of Biological Chemistry</i> , 1995, 270, 22129-22134.	3.4	113
89	Reactive Oxygen Intermediates (ROIs) Are Involved in the Intracellular Transduction of Angiotensin II Signal in C2C12 Cells. <i>Annals of the New York Academy of Sciences</i> , 1995, 752, 394-405.	3.8	25
90	Hepatitis B virus X gene product acts as a transactivator in vivo. <i>Journal of Hepatology</i> , 1994, 21, 103-109.	3.7	50

#	ARTICLE	IF	CITATIONS
91	Induction of the DNA-binding activity of c-jun/c-fos heterodimers by the hepatitis B virus transactivator pX.. <i>Molecular and Cellular Biology</i> , 1994, 14, 989-998.	2.3	146
92	The AP1 Transcription Factor as a Model to Study the Modulation of Intracellular Signalling Pathways by the Hepatitis B Virus Transactivator pX. , 1994, , 748-752.		0
93	Characterization of the hepatitis B virus transactivators: A possible direct role of the virus in the development of hepatocellular carcinoma. <i>Journal of Surgical Oncology</i> , 1993, 53, 34-36.	1.7	1
94	Detection of replicative intermediates of viral RNA in peripheral blood mononuclear cells from chronic hepatitis C virus carriers. , 1993, 8, 23-29.		11
95	The hepatitis B virus X gene product transactivates the HIV-LTR in vivo. , 1993, 8, 63-71.		4
96	A Second-Generation Hepatitis C Virus Confirmatory Test for Chronic Hepatitis B Virus Infection. <i>Journal of Infectious Diseases</i> , 1992, 165, 180-180.	4.0	2
97	Characterization of the hepatitis B virus preS/S region encoded transcriptional transactivator. <i>Virology</i> , 1992, 187, 663-670.	2.4	38
98	Antibodies to hepatitis C virus in patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 1991, 12, 60-63.	3.7	64
99	Full-length and truncated versions of the hepatitis B virus (HBV) X protein (pX) transactivate the cMYC protooncogene at the transcriptional level. <i>Biochemical and Biophysical Research Communications</i> , 1991, 176, 985-992.	2.1	116
100	Significance of anti-HBx antibodies in hepatitis B virus infection. <i>Hepatology</i> , 1991, 13, 143-149.	7.3	37
101	Hepatitis B virus (HBV) X gene expression in human cells and anti-HBx antibodies detection in chronic HBV infection. <i>Virology</i> , 1990, 174, 299-304.	2.4	42
102	Liver-derived T cell clones in autoimmune chronic active hepatitis: Accessory cell function of hepatocytes expressing class II major histocompatibility complex molecules. <i>Clinical Immunology and Immunopathology</i> , 1990, 54, 382-394.	2.0	28
103	Expression of class I and class II major histocompatibility complex antigens on human hepatocytes. <i>Hepatology</i> , 1988, 8, 449-454.	7.3	175
104	DN-p73 is activated after DNA damage in a p53-dependent manner to regulate p53-induced cell cycle arrest. , 0, .		2